Percusurge

Percusurge pioneered the concept of embolic protection during interventional procedures, revolutionizing the field of interventional cardiology by recognizing and solving the problem of distal embolization. Its initial product, the Guardwire^tm, was designed to capture material dislodged within arteries, and to prevent clots/debris from traveling to other parts of Body/Brain. The company's initial clinical trials in 2000 showed that its device reduced major coronary adverse events by 50%, and it was subsequently purchased by Medtronic for $225 million.

The company was founded in 1995 with an initial investment of $40million, and its early investors realized 14X their capital invested.